Zydus Cadila to make indigenous Covid-19 test kits

Our Bureau Ahmedabad | Updated on May 11, 2020 Published on May 11, 2020

File photo

To start manufacturing of ‘Covid Kavach Elisa’ at Ahmedabad facility

Ahmedabad-based Cadila Healthcare Ltd has said in a regulatory filing that it has been provided with technology to make and market the country’s first anti-SARS-Cov-2 human IgG Elisa test kit.

The kit will be used for antibody detection of Covid-19, a disease caused by the coronavirus infection.

Zydus Cadila said it will manufacture ‘Covid Kavach Elisa’, claimed to be the first indigenously developed IgG Elisa test for antibody detection by the Indian Council of Medical Research (ICMR), National Institute of Virology (NIV), Pune.

“The kits will be manufactured through a tech transfer by Cadila Healthcare Ltd at Moraiya, Ahmedabad,” the company said.

Earlier, Union Health Minister Harsh Vardhan, in a social media post, had said: “National Institute of Virology, Pune, has successfully developed the first indigenous anti-SARS-Cov-2 human IgG Elisa test kit for antibody detection of Covid-19. This robust test will play a critical role in surveillance of proportion of population exposed to SARSCoV2 infection.”

ICMR-NIV’s test kit was validated at two sites in Mumbai and has been found to have high sensitivity and specificity, said Cadila. In addition, the kit will have the advantage of testing 90 samples together in a single run of 2.5 hours, it added. Moreover, Elisa-based testing is easily possible even at the district level.

Technology transfer

After development at ICMR-NIV, technology has been transferred to Zydus Cadila for mass scale production.

Initial reports had suggested that ICMR had granted approvals for two types of test kits. The first is a real-time polymerase chain reaction test, which is conducted in a laboratory and requires nasal and throat swabs. The test takes up to eight hours to give results and is stated to be a confirmatory molecular test.

The second type of test is rapid antibody test, which is primarily testing blood to detect Covid-19 antibodies. The results can be obtained in 30 minutes.

However, India had a bad experience in the rapid anti-body test kits that were imported from China, which were found to have an accuracy rate of 6-30 per cent. The tests showed false positive and false negative results with multiple instances of failure.

Meanwhile, Zydus Cadila is already working on developing a vaccine for Covid-19. The development is currently at the animal trial phase and is expected to soon progress towards clinical trials in a few months.

On Monday, Cadila Healthcare shares gained over 2 per cent to trade at Rs 328.25 in early trade.

Published on May 11, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.